{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T08:23:49Z","timestamp":1794039829683,"version":"4.8.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009550","name":"Hasselt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaut.2026.103598","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:19:37Z","timestamp":1784607577000},"page":"103598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Itolizumab targets the CD6-ALCAM axis to limit T-cell responses and brain barrier diapedesis in multiple sclerosis"],"prefix":"10.1016","volume":"163","author":[{"given":"Cynthia","family":"Gonz\u00e1lez-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulien","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doryssa","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Hoeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirre","family":"De Bondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayel","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart Van","family":"Wijmeersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Schroten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Crombet-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayrel","family":"Labrada-Mon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bieke","family":"Broux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-406X","authenticated-orcid":false,"given":"Niels","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaut.2026.103598_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/08923973.2024.2330642","article-title":"Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches","volume":"46","author":"Aliyu","year":"2024","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.jaut.2026.103598_bib2","article-title":"Therapeutic advances in multiple sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Neurol."},{"issue":"24","key":"10.1016\/j.jaut.2026.103598_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417510","article-title":"CD6 and its interacting partners: newcomers to the block of cancer immunotherapies","volume":"24","author":"Aragon-Serrano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jaut.2026.103598_bib4","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201011","article-title":"The T cell CD6 receptor operates a multitask signalosome with opposite functions in T cell activation","volume":"218","author":"Mori","year":"2021","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12964-024-01658-y","article-title":"The CD6 interactome orchestrates ligand-independent T cell inhibitory signaling","volume":"22","author":"Santos","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.jaut.2026.103598_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1571590","article-title":"The OT-II model reveals dual in vitro and in vivo immunomodulatory properties of CD6 in T cell activation","volume":"16","author":"Leyton-Pereira","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103598_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2174\/1389450116666150531152439","article-title":"Tuning T cell activation: the function of CD6 at the immunological synapse and in T cell responses","volume":"17","author":"Santos","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jaut.2026.103598_bib8","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.3389\/fimmu.2018.02994","article-title":"CD6, a rheostat-type signalosome that tunes T cell activation","volume":"9","author":"Goncalves","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2026.103598_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3389\/fimmu.2017.00769","article-title":"Human CD6 down-modulation following T-Cell activation compromises lymphocyte survival and proliferative responses","volume":"8","author":"Carrasco","year":"2017","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2026.103598_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41423-018-0089-9","article-title":"Failure of a T cell regulator: CD6 contributes to the aggravation of autoimmune inflammation","volume":"16","author":"Meyer","year":"2019","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib11","article-title":"The CD6-ALCAM pathway selectively modulates pathogenic T cell migration","volume":"208","author":"Marrocco","year":"2022","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2026.103598_bib12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41423-018-0015-1","article-title":"The role of CD6 in autoimmune diseases","volume":"15","author":"Fox","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2026.103598_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells14040272","article-title":"CD6 in human disease","volume":"14","author":"Gurrea-Rubio","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.jaut.2026.103598_bib14","article-title":"Ligands of CD6: roles in the pathogenesis and treatment of cancer","volume":"15","author":"Gurrea-Rubio","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.jaut.2026.103598_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105315","article-title":"Contribution of evolutionary selected immune gene polymorphism to immune-related disorders: the case of lymphocyte scavenger receptors CD5 and CD6","volume":"22","author":"Casado-Llombart","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.jaut.2026.103598_bib16","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1073\/pnas.1615253114","article-title":"CD6 as a potential target for treating multiple sclerosis","volume":"114","author":"Li","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.jaut.2026.103598_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ebiom.2019.08.008","article-title":"Modulation of CD4 T cell function via CD6-targeting","volume":"47","author":"Freitas","year":"2019","journal-title":"EBioMedicine"},{"issue":"33","key":"10.1016\/j.jaut.2026.103598_bib18","doi-asserted-by":"crossref","first-page":"E6912","DOI":"10.1073\/pnas.1704008114","article-title":"CD318 is a ligand for CD6","volume":"114","author":"Enyindah-Asonye","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA."},{"issue":"8","key":"10.1016\/j.jaut.2026.103598_bib19","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1177\/0271678X16678639","article-title":"ALCAM (CD166) is involved in extravasation of monocytes rather than T cells across the blood-brain barrier","volume":"37","author":"Lyck","year":"2017","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"6","key":"10.1016\/j.jaut.2026.103598_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.36.6.777","article-title":"Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12","volume":"36","author":"Hafler","year":"1986","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jaut.2026.103598_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180088","article-title":"T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab","volume":"12","author":"Bughani","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jaut.2026.103598_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4161\/mabs.28376","article-title":"Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab","volume":"6","author":"Aira","year":"2014","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.jaut.2026.103598_bib23","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10067-015-2988-9","article-title":"Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study","volume":"35","author":"Chopra","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147334","article-title":"The CD6\/ALCAM pathway promotes lupus nephritis via T cell-mediated responses","volume":"132","author":"Chalmers","year":"2022","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.jaut.2026.103598_bib25","first-page":"214","article-title":"Capturing pathogenic immune cells before they home to brain","volume":"2","author":"Steinman","year":"2021","journal-title":"M\u00e9d. Sur"},{"issue":"2","key":"10.1016\/j.jaut.2026.103598_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00401-022-02445-0","article-title":"Oncostatin M triggers brain inflammation by compromising blood-brain barrier integrity","volume":"144","author":"Hermans","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.jaut.2026.103598_bib27","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/jnr.20117","article-title":"Cytokine-induced cell death in human oligodendroglial cell lines. II: alterations in gene expression induced by interferon-gamma and tumor necrosis factor-alpha","volume":"76","author":"Buntinx","year":"2004","journal-title":"J. Neurosci. Res."},{"issue":"7","key":"10.1016\/j.jaut.2026.103598_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167457","article-title":"Rapamycin rescues loss of function in blood-brain barrier-interacting Tregs","volume":"9","author":"Baeten","year":"2024","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-2478(90)90030-T","article-title":"Differential expression of the Lfa-1 molecule on the human peripheral-blood mononuclear cell subpopulations","volume":"24","author":"Desroches","year":"1990","journal-title":"Immunol. Lett."},{"issue":"3","key":"10.1016\/j.jaut.2026.103598_bib30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2008.12.020","article-title":"Lymphocyte crawling and transendothelial migration require chemokine triggering of high-affinity LFA-1 integrin","volume":"30","author":"Shulman","year":"2009","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12987-023-00504-6","article-title":"Cerebral microvascular endothelial cell-derived extracellular vesicles regulate blood - brain barrier function","volume":"20","author":"Hosseinkhani","year":"2023","journal-title":"Fluids Barriers CNS"},{"issue":"4","key":"10.1016\/j.jaut.2026.103598_bib32","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029025","article-title":"Effector T cells in multiple sclerosis","volume":"8","author":"Kaskow","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"19","key":"10.1016\/j.jaut.2026.103598_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910625","article-title":"Blood-brain barrier disruption in neuroimmunological disease","volume":"25","author":"Shimizu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12979-020-00207-8","article-title":"An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients","volume":"17","author":"Saavedra","year":"2020","journal-title":"Immun. Ageing"},{"issue":"8","key":"10.1016\/j.jaut.2026.103598_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26083532","article-title":"Breaking the barrier: the role of proinflammatory cytokines in BBB dysfunction","volume":"26","author":"Gryka-Marton","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2026.103598_bib36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2017.00594","article-title":"Relevance of CD6-Mediated interactions in the regulation of peripheral T-Cell responses and tolerance","volume":"8","author":"Consuegra-Fernandez","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2026.103598_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.827786","article-title":"T cell interaction with activated endothelial cells primes for tissue-residency","volume":"13","author":"Wienke","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/brain\/awad286","article-title":"ALCAM on human oligodendrocytes mediates CD4 T cell adhesion","volume":"147","author":"Jamann","year":"2024","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jaut.2026.103598_bib39","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2174\/1389450117666160201114308","article-title":"Therapeutic targeting of CD6 in autoimmune diseases: a review of Cuban clinical studies with the antibodies IOR-T1 and itolizumab","volume":"17","author":"Hernandez","year":"2016","journal-title":"Curr. Drug Targets"},{"issue":"2","key":"10.1016\/j.jaut.2026.103598_bib40","article-title":"Memory cells in infection and autoimmunity: mechanisms, functions, and therapeutic implications","volume":"13","author":"Giri","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jaut.2026.103598_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109025","article-title":"Th1 and Th17 cells are resistant towards T cell activation-induced downregulation of CD6","volume":"238","author":"Bruck","year":"2022","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2026.103598_bib42","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ecco-jcc\/jjy179","article-title":"Critical role of CD6highCD4+ T cells in driving Th1\/Th17 cell immune responses and mucosal inflammation in IBD","volume":"13","author":"Ma","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2026.103598_bib43","article-title":"CD6-ALCAM signaling is upregulated in kidneys with Lupus nephritis and is associated with disease activity","volume":"71","author":"Der","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"1\u20132","key":"10.1016\/j.jaut.2026.103598_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jneuroim.2014.08.620","article-title":"High CD6 and low chemokine receptor expression on peripheral blood lymphocytes correlates with MRI gadolinium enhancement in MS","volume":"276","author":"Jurewicz","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jaut.2026.103598_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ni1551","article-title":"Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system","volume":"9","author":"Cayrol","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2026.103598_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.967944","article-title":"Intrahepatic activated leukocyte cell adhesion molecule induces CD6(high)CD4(+) T cell infiltration in autoimmune hepatitis","volume":"13","author":"Qian","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.jaut.2026.103598_bib47","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/cyto.a.22513","article-title":"Human treg cells are characterized by low\/negative CD6 expression","volume":"85","author":"Garcia Santana","year":"2014","journal-title":"Cytometry A"},{"issue":"7","key":"10.1016\/j.jaut.2026.103598_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2153534","article-title":"Regulatory T cell therapy for multiple sclerosis: breaching (blood-brain) barriers","volume":"18","author":"Verreycken","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"issue":"21","key":"10.1016\/j.jaut.2026.103598_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162788","article-title":"CD8+ T cells recognizing a neuron-restricted antigen injure axons in a model of multiple sclerosis","volume":"133","author":"Clarkson","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jaut.2026.103598_bib50","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3389\/fimmu.2017.01160","article-title":"Cytotoxic CD4+ T cells drive multiple sclerosis progression","volume":"8","author":"Peeters","year":"2017","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2026.103598_bib51","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100822RR","article-title":"CD44 mediates shear stress mechanotransduction in an in vitro blood-brain barrier model through small GTPases RhoA and Rac1","volume":"36","author":"DeOre","year":"2022","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.jaut.2026.103598_bib52","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.4103\/1673-5374.253521","article-title":"Galectin-3 prospects as a therapeutic agent for multiple sclerosis","volume":"14","author":"Thomas","year":"2019","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.jaut.2026.103598_bib53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.brainres.2015.07.033","article-title":"Galectin-1 suppresses methamphetamine induced neuroinflammation in human brain microvascular endothelial cells: neuroprotective role in maintaining blood brain barrier integrity","volume":"1624","author":"Parikh","year":"2015","journal-title":"Brain Res."},{"issue":"18","key":"10.1016\/j.jaut.2026.103598_bib54","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157038","article-title":"CDCP1 regulates retinal pigmented epithelial barrier integrity for the development of experimental autoimmune uveitis","volume":"7","author":"Zhang","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12987-019-0165-2","article-title":"Human CD4(+) T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in vitro","volume":"17","author":"Nishihara","year":"2020","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib56","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2209944120","article-title":"Enhanced pathogenicity of Th17 cells due to natalizumab treatment: implications for MS disease rebound","volume":"120","author":"Janoschka","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"50","key":"10.1016\/j.jaut.2026.103598_bib57","doi-asserted-by":"crossref","first-page":"18246","DOI":"10.1523\/JNEUROSCI.2473-12.2012","article-title":"Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling","volume":"32","author":"Martinez Gomez","year":"2012","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.jaut.2026.103598_bib58","doi-asserted-by":"crossref","first-page":"E524","DOI":"10.1073\/pnas.1614336114","article-title":"Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis","volume":"114","author":"Lecuyer","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.jaut.2026.103598_bib59","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2005-09-3881","article-title":"Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells","volume":"107","author":"Zimmerman","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib60","article-title":"Surface CD6 regulates T cell adhesion and migration through direct ligand interaction and stabilization of VLA4","volume":"212","author":"Ampudia","year":"2024","journal-title":"J. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.jaut.2026.103598_bib61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jneuroim.2010.07.012","article-title":"Natalizumab treatment reduces endothelial activity in MS patients","volume":"227","author":"Millonig","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ph18010104","article-title":"Targeting cytokine-mediated inflammation in brain disorders: developing new treatment strategies","volume":"18","author":"Mallick","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.jaut.2026.103598_bib63","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/jleuko\/qiad124","article-title":"CD6 triggers actomyosin cytoskeleton remodeling after binding to its receptor complex","volume":"115","author":"Borjini","year":"2024","journal-title":"J. Leukoc. Biol."},{"issue":"7","key":"10.1016\/j.jaut.2026.103598_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115960","article-title":"Acquisition of residency programs by T cells entering the human brain","volume":"44","author":"Hsiao","year":"2025","journal-title":"Cell Rep."},{"issue":"640","key":"10.1016\/j.jaut.2026.103598_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl6058","article-title":"Tissue-resident memory CD8 T cells cooperate with CD4 T cells to drive compartmentalized immunopathology in the CNS","volume":"14","author":"Vincenti","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.jaut.2026.103598_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020409","article-title":"Tissue-resident memory T cells in chronic inflammation-local cells with systemic effects?","volume":"10","author":"Samat","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jaut.2026.103598_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102453","article-title":"The pivotal role of CD69 in autoimmunity","volume":"111","author":"Gorabi","year":"2020","journal-title":"J. Autoimmun."},{"issue":"34","key":"10.1016\/j.jaut.2026.103598_bib68","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025813118","article-title":"Pro-inflammatory T helper 17 directly harms oligodendrocytes in neuroinflammation","volume":"118","author":"Larochelle","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.jaut.2026.103598_bib69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/14737175.2020.1750955","article-title":"The therapeutic potential of galectin-1 and galectin-3 in the treatment of neurodegenerative diseases","volume":"20","author":"Ramirez Hernandez","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jaut.2026.103598_bib70","article-title":"Cell-surface proteomic profiling identifies CD72 as a regulator of microglial tiling","author":"Chan","year":"2025","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.jaut.2026.103598_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neulet.2012.05.048","article-title":"CD44 expression in astrocytes and microglia is associated with ALS progression in a mouse model","volume":"520","author":"Matsumoto","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jaut.2026.103598_bib72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jneuroim.2018.08.004","article-title":"CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients","volume":"323","author":"Mohammadzadeh","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.jaut.2026.103598_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/genes13081319","article-title":"The role of cytotoxic T-Lymphocyte antigen 4 in the pathogenesis of multiple sclerosis","volume":"13","author":"Basile","year":"2022","journal-title":"Genes"},{"issue":"12","key":"10.1016\/j.jaut.2026.103598_bib74","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1007\/s12035-021-02495-7","article-title":"Role of the PD-1\/PD-L1 signaling in multiple sclerosis and experimental autoimmune encephalomyelitis: recent insights and future directions","volume":"58","author":"Mi","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.jaut.2026.103598_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080721","article-title":"Regulation of CTLA-4 and PD-L1 expression in relapsing-remitting multiple sclerosis patients after treatment with fingolimod, IFNbeta-1alpha, Glatiramer acetate, and Dimethyl fumarate drugs","volume":"11","author":"Derakhshani","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.jaut.2026.103598_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.679413","article-title":"IL-17 inhibits oligodendrocyte progenitor cell proliferation and differentiation by increasing K(+) channel Kv1.3","volume":"15","author":"Liu","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.jaut.2026.103598_bib77","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cytogfr.2014.07.013","article-title":"IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments","volume":"25","author":"Luchtman","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"10.1016\/j.jaut.2026.103598_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12969","article-title":"CNS inflammation after natalizumab therapy for multiple sclerosis: a retrospective histopathological and CSF cohort study","volume":"31","author":"H\u00e4usler","year":"2021","journal-title":"Brain Pathol."},{"issue":"12","key":"10.1016\/j.jaut.2026.103598_bib79","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1084\/jem.20110434","article-title":"Th17 lymphocytes traffic to the central nervous system independently of \u03b14 integrin expression during EAE","volume":"208","author":"Rothhammer","year":"2011","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.jaut.2026.103598_bib80","article-title":"Disrupted balance of T cells under natalizumab treatment in multiple sclerosis","volume":"3","author":"Kimura","year":"2016","journal-title":"Neurol-Neuroimmunol"},{"issue":"4","key":"10.1016\/j.jaut.2026.103598_bib81","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10875-011-9522-x","article-title":"Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism","volume":"31","author":"Ramos-Cejudo","year":"2011","journal-title":"J. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.jaut.2026.103598_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052208","article-title":"Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis","volume":"7","author":"Benkert","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jaut.2026.103598_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047578","article-title":"Effect of natalizumab on circulating CD4+ T-Cells in multiple sclerosis","volume":"7","author":"B\u00f6rnsen","year":"2012","journal-title":"PLoS One"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:27:02Z","timestamp":1794036422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":83,"alternative-id":["S0896841126000764"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103598","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Itolizumab targets the CD6-ALCAM axis to limit T-cell responses and brain barrier diapedesis in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103598"}}